Candidiasis, Vulvovaginal Clinical Trial
Official title:
A Multi-Center Randomized Study to Evaluate the Safety, Tolerability, and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) Compared With Oral Fluconazole in the Treatment of Moderate to Severe Vulvovaginal Candidiasis (VVC)
This is a multi-center, randomized study to evaluate the safety, tolerability, and efficacy of 200 mg CAMB and 400 mg CAMB compared with a single 150 mg dose of fluconazole in the treatment of moderate to severe VVC.
This is a multi-center, randomized study to evaluate the safety, tolerability, and efficacy
of 200 mg CAMB and 400 mg CAMB compared with a single 150 mg dose of fluconazole in the
treatment of moderate to severe VVC.
Approximately 75 women with moderate to severe VVC will be randomized to 1 of 3 treatment
groups (200 mg CAMB, 400 mg CAMB, or fluconazole) to achieve approximately 25 subjects in
each group. The primary objective of this study is to evaluate the safety of 200 mg and 400
mg doses of oral CAMB for 5 days compared with a single 150 mg dose of oral fluconazole in
subjects with moderate to severe VVC. The secondary efficacy objectives of this study
included the clinical cure rate, mycology eradication and responder outcome. Tertiary
objectives include pharmacokinetics.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02251093 -
Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis
|
Phase 3 | |
Completed |
NCT01293643 -
A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077)
|
Phase 3 | |
Not yet recruiting |
NCT04626258 -
Fluconazol Versus Medical Honey in the Treatment of Recurrent Vulvovaginal Candidiasis
|
Phase 4 | |
Completed |
NCT02733432 -
RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections
|
Phase 2 | |
Completed |
NCT02248506 -
Epidemiological Study About the Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis
|
Phase 4 | |
Completed |
NCT02730494 -
Study Evaluating the Optimal Dosage for Equivalence Between Lcr Regenerans® Capsules and Tablets (Lactobacillus Rhamnosus Lcr35®) on the Vaginal Flora Colonisation
|
Phase 1 | |
Completed |
NCT02180828 -
Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis
|
Phase 4 | |
Recruiting |
NCT04930107 -
Vulvovaginal Candidiasis in Canadian Females
|
Early Phase 1 | |
Withdrawn |
NCT03167957 -
Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis
|
Phase 2 | |
Recruiting |
NCT05367089 -
The Effect of Medical Grade Honey Formulation (L-Mesitran) Administration on Recurrent Vulvovaginal Candidiasis Symptoms
|
Phase 3 | |
Terminated |
NCT02859493 -
Effect of Saccharomyces Cerevisiae on Vulvo-vaginal Candidiasis
|
N/A | |
Completed |
NCT01891331 -
A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)
|
Phase 2 | |
Completed |
NCT02888197 -
Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization
|
N/A | |
Completed |
NCT03975569 -
Study of the Vaginal Microbiota and the Potential of a Vaginal Probiotic Cream in Vaginal Candidosis
|
N/A | |
Recruiting |
NCT05059145 -
A Clinical Trial for Chlorhexidine as Treatment for Vulvovaginal Candidiasis
|
Phase 2 | |
Recruiting |
NCT03075046 -
Use of 405nm Blue Light Emitting Diode in the Treatment of Women With Vulvovaginal Candidiasis: a Clinical Trial
|
N/A |